Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 6 Base case results by country, one-year time horizon

From: A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe

Country

Current care

Rectal diazepam

Unlicensed buccal midazolam

BUCCOLAM

Costs

QALYs

No of ambulance call-outs

Costs

QALYs

No of ambulance call-outs

Costs

QALYs

No of ambulance call-outs

Costs

QALYs

No of ambulance call-outs

Scotland

€5,544

0.75030

8.31

€6,997

0.74475

11.45

€5,544

0.75030

8.31

€5,145

0.75112

7.83

Wales

€5,019

0.68030

6.23

€7,539

0.67016

9.65

€4,565

0.68231

6.05

€4,412

0.68458

5.87

Germany

€13,278

0.69522

12.99

€13,340

0.69520

13.04

N/A

€ 9,770

0.69662

9.20

Spain

€12,862

0.74736

8.34

€12,862

0.74736

8.34

€7,378

0.75543

4.69

France

€8,550

0.47491

3.02

€8,550

0.47491

3.02

€5,913

0.47516

2.07

Italy

€6,214

0.38552

3.96

€6,214

0.38552

3.96

€4,674

0.38808

2.92

Switzerland

€27,174

0.68921

2.99

€28,588

0.68916

3.15

€17,777

0.68957

1.94

Country

Incremental versus current care

Incremental versus rectal diazepam

Incremental versus unlicensed buccal midazolam

Costs

QALYs

Ambulance call-outs avoided

ICER

Costs

QALYs

Ambulance call-outs avoided

ICER

Costs

QALYs

Ambulance call-outs avoided

ICER

Scotland

–€399

0.00082

0.48

Dominant a

–€1,852

0.00637

3.62

Dominant a

–€399

0.00082

0.48

Dominant a

Wales

–€607

0.00429

0.36

Dominant a

–€3,127

0.01442

3.79

Dominant a

–€153

0.00227

0.18

Dominant a

Germany

–€3,507

0.00140

3.79

Dominant a

–€3,569

0.00142

3.84

Dominant a

N/A

Spain

–€5,484

0.00807

3.64

Dominant a

–€5,484

0.00807

3.64

Dominant a

France

–€2,637

0.00025

0.95

Dominant a

–€2,637

0.00025

0.95

Dominant a

Italy

–€1,540

0.00256

1.03

Dominant a

–€1,540

0.00256

1.03

Dominant a

Switzerland

–€9,397

0.00036

1.05

Dominant a

–€10,811

0.00041

1.21

Dominant a

  1. ICER = incremental cost-effectiveness ratio; N/A = not applicable as unlicensed buccal midazolam is not used in these countries; QALY = quality-adjusted life-year.
  2. a Dominant means that BUCCOLAM is both cost saving and results in positive outcomes when compared with the relevant comparator.
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us